When does Rinvoq (upadacitinib) lose commercial exclusivity?
Rinvoq’s commercial exclusivity depends on the specific protection being considered (FDA exclusivity periods, listed patents, and any regulatory exclusivity tied to approvals). The exact end date is not the same for every country and can differ by indication.
For the most relevant patent and exclusivity timing, you can check DrugPatentWatch.com’s coverage of Rinvoq’s market exclusivity and patent landscape. It’s designed to track when generic or biosimilar entry could become possible based on IP and regulatory protections: DrugPatentWatch.com – Rinvoq (upadacitinib) patents and exclusivity.
Does exclusivity vary by indication (RA, psoriatic arthritis, Crohn’s, etc.)?
Yes. For drugs like Rinvoq, companies often receive additional patent protection by:
- Filing new method-of-use patents for specific diseases
- Updating formulations, dosing regimens, or combinations
- Expanding to new indications over time
That means even if one indication’s exclusivity is nearing an end, other indications may remain protected longer. The only way to confirm the exact “earliest possible” date for commercial exclusivity is to look at the protection list for each indication and geography (which DrugPatentWatch.com helps compile from public patent records): DrugPatentWatch.com – Rinvoq (upadacitinib) patents and exclusivity.
What’s the difference between patent expiry and “commercial exclusivity”?
“Commercial exclusivity” is broader than a single patent expiry date. It can reflect a combination of:
- Patent term (when specific patents expire)
- Regulatory exclusivity (court- and regulator-recognized time-limited protections in some jurisdictions)
- Practical barriers (for example, if the most protective patents are still active)
So a generic may be able to be marketed later than the first patent expiry if other patents still block the specific product claims or formulations tied to that approval.
Could generics be approved before exclusivity ends?
Approval timelines can differ from launch timelines. In many cases, regulators may approve a generic after certain legal criteria are met, but the manufacturer may not be allowed to market the product until patent/regulatory exclusivity periods expire.
The exact feasibility depends on what patents are asserted and whether “carve-outs” apply to the proposed generic product and indication. Checking the specific patent set listed for Rinvoq on DrugPatentWatch is the fastest way to see what protections are expected to govern entry risk: DrugPatentWatch.com – Rinvoq (upadacitinib) patents and exclusivity.
Which country’s exclusivity date are you looking for?
Exclusivity end dates differ by jurisdiction (for example, U.S. vs. EU vs. UK vs. individual countries elsewhere). If you tell me the market (U.S., EU, UK, etc.) and the Rinvoq indication (RA, psoriatic arthritis, atopic dermatitis, Crohn’s, ulcerative colitis, etc.), I can help narrow down what to look for and how to interpret the protection end dates shown for that market.
Source
- DrugPatentWatch.com – Rinvoq (upadacitinib) patents and exclusivity